Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Undermining the Foundation: High Stakes in Fight Over Reagan-Udall

This article was originally published in RPM Report

Executive Summary

The Reagan-Udall Foundation is the one piece of the FDA drug safety law enacted in 2007 that both FDA and industry are excited about. Congressional appropriators, however, have serious concerns. The stakes are higher than they seem: in the short run, the Critical Path and active surveillance systems may depend on the foundation. In the long run, the question is whether industry has any say in the evolution of regulation.

You may also be interested in...



Sentinel and Phase IV: A Dilemma For FDA and Industry

FDA and industry are both interesting in tapping into Sentinel as an alternative to traditional Phase IV studies. But how can FDA require use of the new capability without having to pay for it?

Surveying the Landscape for Active Surveillance

The transition away from spontaneous adverse event reporting systems to real-time active surveillance is under way, but far from complete. Alan Goldhammer, the former head of regulatory affairs at the Pharmaceutical Research & Manufacturers of America trade association, surveys the landscape of active surveillance activities.

Sustainable Funding for Regulatory Science: FDA, Industry Hope Fourth Time is the Charm

FDA is trying one more time to secure significant resources to fund regulatory science. FDA's leadership is making good progress with key figures in the Administration and on the Hill-but the money still isn't there.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS080435

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel